Every material Form 8-K CareDx, Inc. has filed with the SEC since July 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
CareDx reported third-quarter 2026 revenue of $139 million, up 39% from a year earlier, and GAAP net income of $19 million, compared with $2 million in the third quarter of 2025. The company raised its full-year 2026 revenue guidance to $520 million to $530 million and its adjusted EBITDA guidance to $90 million to $100 million, which points to higher expected results for shareholders.
Q3 2026 revenue was $139 million, up 39% year-over-year; Testing Services revenue was $119 million, up 65%.
GAAP diluted net income per share was $0.35, compared with $0.03 in the third quarter of 2025; net income included an $8.6 million income tax benefit.
2026 revenue guidance raised to $520 million to $530 million, from $490 million to $500 million previously.
2026 adjusted EBITDA guidance raised to $90 million to $100 million, from $66 million to $78 million previously.
CareDx reported second-quarter 2026 revenue of $132 million, up 52% from a year earlier, and GAAP net income of $111 million, which includes a $113 million gain on the sale of its Lab Products business. The company raised its full-year 2026 revenue guidance to $490 million to $500 million and its adjusted EBITDA guidance to $66 million to $78 million.
Revenue of $132 million versus $87 million in Q2 2025; Testing Services revenue rose 61% to $100 million.
GAAP diluted net income per share was $2.07, versus a loss of $0.16; non-GAAP diluted net income per share was $0.37, versus $0.10.
Adjusted EBITDA was $25 million versus $5 million in Q2 2025.
2026 guidance raised: revenue to $490 million to $500 million (from $447 million to $465 million) and adjusted EBITDA to $66 million to $78 million (from $43 million to $57 million).
CareDx completed the sale of its Lab Products business to Eurobio Scientific on June 30, 2026, and the acquisition of Naveris, maker of the NavDx cancer test, on July 1, 2026. The company will include Naveris in its consolidated results from the third quarter of 2026, and it plans to give financial impact details on the sale during its second quarter 2026 earnings call.
Eurobio sale closed June 30, 2026; the 8-K reports $171.7 million in cash, subject to customary adjustments, while the press release cites $171.2 million at closing.
Naveris acquisition closed July 1, 2026, for $161.8 million in cash, subject to adjustments, plus up to $100.0 million in contingent cash tied to 2026 and 2027 revenue milestones.
The press release says Naveris generated approximately $35 million in revenue in 2025 and that NavDx has Medicare coverage for HPV-driven head and neck and anal cancer MRD testing.
Financial statements of Naveris and pro forma information will be filed by amendment within 71 calendar days.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CareDx, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →